Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Payables (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Payables for 4 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 14.44% to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a 14.44% increase, with the full-year FY2025 number at $3.7 million, up 14.44% from a year prior.
  • Payables was $3.7 million for Q4 2025 at Day One Biopharmaceuticals, down from $5.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.4 million in Q2 2024 to a low of $260000.0 in Q4 2022.
  • A 4-year average of $3.3 million and a median of $3.5 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: skyrocketed 890.77% in 2023, then fell 21.01% in 2025.
  • Day One Biopharmaceuticals' Payables stood at $260000.0 in 2022, then surged by 890.77% to $2.6 million in 2023, then grew by 26.63% to $3.3 million in 2024, then increased by 14.44% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Payables are $3.7 million (Q4 2025), $5.1 million (Q2 2025), and $2.5 million (Q1 2025).